Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walid Shalata

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Cancers|April 14, 2025
Correlation Between Body Mass Index and Immunotherapy Response in Advanced NSCLCWalid Shalata, Itamar Gothelf, Yulia Dudnik, et al.
Immunotherapy|May 10, 2021
Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacyIlya Polishchuk, Alexander Yakobson, Melanie Zemel, et al.
Frontiers in Molecular Biosciences|May 11, 2026
Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLCWalid Shalata, Bilal Krayim, Asmah Miari, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)Urska Janzic, Natalie Maimon Rabinovich, Walid Shalata, et al.
Frontiers in Immunology|December 8, 2025
Worse prognosis of local and locally advanced head and neck Merkel cell carcinoma: Is it time to change the treatment paradigm?Ronen Brenner, Hanna T Frumin Edri, Ina Sarel, et al.
Cancers|March 28, 2025
Is the Addition of Chemotherapy to Adjuvant Radiation in Merkel Cell Cancer Beneficial? Real-World Data with Long-Term Follow-UpWalid Shalata, Hanna T Frumin Edri, Ina Sarel, et al.
Diagnostics (Basel, Switzerland)|March 14, 2026
Sun-Exposed vs. Non-Sun-Exposed Areas: Epidemiology and Pathogenesis of Non-Metastatic Merkel Cell CarcinomaAlexander Yakobson, Ronen Brenner, Hanna T Frumin Edri, et al.
International Journal of Molecular Sciences|February 13, 2026
Impact of Statin Use on Immunotherapy Outcomes and Efficacy in Non-Small Cell Lung Cancer PatientsAlexander Yakobson, Abed Agbarya, Yulia Dudnik, et al.
Frontiers in Molecular Biosciences|July 9, 2026
Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinibWalid Shalata, Bilal Krayim, Asmah Miari, et al.
Cancers|August 28, 2025
Analysis of Metastases and Second Primary Malignancy Development in Patients with Invasive Transitional Cell Carcinoma of the BladderKeren Rouvinov, Alexander Yakobson, Angela Tiganas, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Cancers|April 14, 2025
Correlation Between Body Mass Index and Immunotherapy Response in Advanced NSCLCWalid Shalata, Itamar Gothelf, Yulia Dudnik, et al.
Immunotherapy|May 10, 2021
Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacyIlya Polishchuk, Alexander Yakobson, Melanie Zemel, et al.
Frontiers in Molecular Biosciences|May 11, 2026
Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLCWalid Shalata, Bilal Krayim, Asmah Miari, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)Urska Janzic, Natalie Maimon Rabinovich, Walid Shalata, et al.
Frontiers in Immunology|December 8, 2025
Worse prognosis of local and locally advanced head and neck Merkel cell carcinoma: Is it time to change the treatment paradigm?Ronen Brenner, Hanna T Frumin Edri, Ina Sarel, et al.
Cancers|March 28, 2025
Is the Addition of Chemotherapy to Adjuvant Radiation in Merkel Cell Cancer Beneficial? Real-World Data with Long-Term Follow-UpWalid Shalata, Hanna T Frumin Edri, Ina Sarel, et al.
Diagnostics (Basel, Switzerland)|March 14, 2026
Sun-Exposed vs. Non-Sun-Exposed Areas: Epidemiology and Pathogenesis of Non-Metastatic Merkel Cell CarcinomaAlexander Yakobson, Ronen Brenner, Hanna T Frumin Edri, et al.
International Journal of Molecular Sciences|February 13, 2026
Impact of Statin Use on Immunotherapy Outcomes and Efficacy in Non-Small Cell Lung Cancer PatientsAlexander Yakobson, Abed Agbarya, Yulia Dudnik, et al.
Frontiers in Molecular Biosciences|July 9, 2026
Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinibWalid Shalata, Bilal Krayim, Asmah Miari, et al.
Cancers|August 28, 2025
Analysis of Metastases and Second Primary Malignancy Development in Patients with Invasive Transitional Cell Carcinoma of the BladderKeren Rouvinov, Alexander Yakobson, Angela Tiganas, et al.
Pageof 8